Cognition Therapeutics has reached an agreement with the FDA on key aspects of its Phase 3 clinical trial for Zervimesine, a drug candidate targeting dementia with Lewy bodies (DLB). The trial will enroll patients with mild-to-moderate DLB, testing a daily 100 mg oral dose against placebo over nine months, focusing on hallucinations and daily function as primary and secondary endpoints. This alignment is crucial as there are currently no approved treatments for DLB, a progressive neurodegenerative disease. The company’s next steps include finalizing the trial protocol and advancing the study to potentially bring the first effective therapy to this underserved patient population.
Cognition Therapeutics' Phase 3 trial for Zervimesine in dementia with Lewy bodies is a key development in neurodegenerative disease treatment. For readers following the health sector, here is Pluang's market snapshot as of Oct 22, 2026 17:11 WIB: out of 150 priced US health stocks, 66 rose and 77 fell. Notable movers include TXG at USD 72.98 with a 1-day change of -3.45% and 100% buy order activity, NUWE at USD 0.54 up 3.34% with 100% buy order activity, and ZBH at USD 97.49 up 2.77%.
Drofa Comms has released the Women Leading the Way Digital Magazine 2026, aiming to highlight women experts in finance on equal terms with men. The digital magazine features insights from 25 industry professionals and covers topics like AI in wealth ...
Fortuna Mining Corp. will announce its financial results for the third quarter of 2026 on November 4, after market close. A conference call to discuss the results will be held on November 5 at 12 p.m. Eastern time, featuring the CEO and key executive...
Gogoro Inc., a leader in battery swapping technology for electric mobility, will announce its financial results for the third quarter ending September 30, 2026, on November 11 before the market opens. The company will hold a webcast at 7 a.m. Eastern...
Regula Forensics contributed expertise to a Forrester Research report on key requirements for Know-Your-Business (KYB) solutions, emphasizing the importance of ongoing verification beyond initial onboarding. The report highlights how Regula's technol...
The LEPAS L6 EV completed its inaugural LEPAS Global Elegance Drive, a 700 km journey from Shanghai to Wuhu, testing its driving dynamics, comfort, smart parking, range, and charging performance. The event involved 34 drivers from 15 countries and in...
